A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C

Journal of Psychosomatic Research

Volumn 78, Issue 2, 2015, Pages 184-192

  Huckans, Marilyn ^a,b   Fuller, Bret ^a,b   Wheaton, Viva ^a,c   Jaehnert, Sarah ^a,c   Ellis, Carilyn ^a,d   Kolessar, Michael ^a,c   Kriz, Daniel ^a,c   Anderson, Jeanne Renee ^a,c   Berggren, Kristin ^a,d   Olavarria, Hannah ^a   Sasaki, Anna W ^a,b   Chang, Michael ^a,b   Flora, Kenneth D ^e   Loftis, Jennifer M ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PACIFIC UNIVERSITY   (United States)

^d GEORGE FOX UNIVERSITY   (United States)

^e Oregon Clinic   (United States)

Author keywords

Anxiety; Cognition; Depression; Fatigue; Hepatitis c; Interferon; Pain

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT;

ADULT; ANXIETY; ARTICLE; ATTENTION; ATTENTION, MEMORY AND EXECUTIVE FUNCTIONS MODULE; BECK DEPRESSION INVENTORY; BRIEF PAIN INVENTORY; COGNITION; CONTROLLED STUDY; DEPRESSION; EXECUTIVE FUNCTION; FATIGUE; FATIGUE SEVERITY SCALE; FEMALE; GENERALIZED ANXIETY DISORDER INVENTORY; HEPATITIS C; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL DISEASE; MENTAL FUNCTION; MIDDLE AGED; NEUROPSYCHOLOGICAL ASSESSMENT BATTERY; NEUROPSYCHOLOGICAL TEST; PAIN; AGED; COMORBIDITY; DRUG EFFECTS; HEPATITIS C, CHRONIC; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; ANXIETY; COGNITION; COMORBIDITY; DEPRESSION; FATIGUE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PAIN; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; VIRAL LOAD;

EID: 84920878851     PISSN: 00223999     EISSN: 18791360     Source Type: Journal    
DOI: 10.1016/j.jpsychores.2014.07.020     Document Type: Article

References (66)

1. Global Burden Of Hepatitis CWG Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004, 44:20-29. [PubMed PMID: 14681338]. 10.1177/0091270003258669.
2. Seeff LB, Hoofnagle JH Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003, 7:261-287. [PubMed PMID: 12691470].
3. Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, et al. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2012, 107:669-689. [quiz 90, PubMed PMID: 22525303]. 10.1038/ajg.2012.48.
4. Hauser P, Morasco BJ, Linke A, Bjornson D, Ruimy S, Matthews A, et al. Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder. Psychosomatics 2009, 50:500-505. [PubMed PMID: 19855036; PubMed Central PMCID: PMC2987665]. 10.1176/appi.psy.50.5.500.
5. Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 2013, 158:114-123. [PubMed PMID: 23437439].
6. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206. [PubMed PMID: 21449783; PubMed Central PMCID: PMC3766849]. 10.1056/NEJMoa1010494.
7. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011, 365:1014-1024. [PubMed PMID: 21916639; PubMed Central PMCID: PMC3809077]. 10.1056/NEJMoa1014463.
8. Loftis JM, Hauser P The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004, 82:175-190. [PubMed PMID: 15488246]. 10.1016/j.jad.2004.04.002.
9. Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 2003, 9:847-854. [PubMed PMID: 14632243].
10. Amodio P, De Toni EN, Cavalletto L, Mapelli D, Bernardinello E, Del Piccolo F, et al. Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. J Affect Disord 2005, 84:93-98. [PubMed PMID: 15620390]. 10.1016/j.jad.2004.09.004.
11. Baranyi A, Meinitzer A, Stepan A, Putz-Bankuti C, Breitenecker RJ, Stauber R, et al. A biopsychosocial model of interferon-alpha-induced depression in patients with chronic hepatitis C infection. Psychother Psychosom 2013, 82:332-340. [PubMed PMID: 23942342]. 10.1159/000348587.
12. Byrnes V, Miller A, Lowry D, Hill E, Weinstein C, Alsop D, et al. Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. J Hepatol 2012, 56:549-556. [PubMed PMID: 22027578]. 10.1016/j.jhep.2011.09.015.
13. Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Litman HJ, Lok AS, et al. Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C. Am J Gastroenterol 2010, 105:1551-1560. [PubMed PMID: 20104219; PubMed Central PMCID: PMC3772520]. 10.1038/ajg.2010.3.
14. Fontana RJ, Bieliauskas LA, Lindsay KL, Back-Madruga C, Wright EC, Snow KK, et al. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology 2007, 45:1154-1163. [PubMed PMID: 17465000]. 10.1002/hep.21633.
15. Hilsabeck RC, Hassanein TI, Ziegler EA, Carlson MD, Perry W Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc 2005, 11:16-22. [PubMed PMID: 15686604]. 10.1017/S1355617705050022.
16. Juengling FD, Ebert D, Gut O, Engelbrecht MA, Rasenack J, Nitzsche EU, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology 2000, 152:383-389. [PubMed PMID: 11140330].
17. Kraus MR, Schafer A, Wissmann S, Reimer P, Scheurlen M Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin Pharmacol Ther 2005, 77:90-100. [PubMed PMID: 15637534]. 10.1016/j.clpt.2004.09.007.
18. Lieb K, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Janssen G, et al. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study. Eur Psychiatry 2006, 21:204-210. [PubMed PMID: 16632167]. 10.1016/j.eurpsy.2004.09.030.
19. Majer M, Welberg LA, Capuron L, Pagnoni G, Raison CL, Miller AH IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav Immun 2008, 22:870-880. [PubMed PMID: 18258414; PubMed Central PMCID: PMC2497339]. 10.1016/j.bbi.2007.12.009.
20. Pattullo V, McAndrews MP, Damyanovich A, Heathcote EJ Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes. Liver Int 2011, 31:1028-1038. [PubMed PMID: 21733093]. 10.1111/j.1478-3231.2011.02549.x.
21. Pawelczyk T, Pawelczyk A, Strzelecki D, Rabe-Jablonska J Pegylated interferon alpha and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients. Gen Hosp Psychiatry 2008, 30:501-508. [PubMed PMID: 19061675]. 10.1016/j.genhosppsych.2008.03.001.
22. Raison CL, Rye DB, Woolwine BJ, Vogt GJ, Bautista BM, Spivey JR, et al. Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol. Biol Psychiatry 2010, 68:942-949. [PubMed PMID: 20537611; PubMed Central PMCID: PMC2937202]. 10.1016/j.biopsych.2010.04.019.
23. Thein HH, Maruff P, Krahn MD, Kaldor JM, Koorey DJ, Brew BJ, et al. Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Med 2007, 8:520-528. [PubMed PMID: 17944685]. 10.1111/j.1468-1293.2007.00505.x.
24. Wobrock T, Mihm U, Lohr C, Hofmann WP, Sarrazin C, Zeuzem S, et al. Cognition in hepatitis C patients treated with pegylated interferon. World J Biol Psychiatry 2009, 10:819-826. [PubMed PMID: 19995219]. 10.1080/15622970701714362.
25. Manos MM, Ho CK, Murphy RC, Shvachko VA Physical, social, and psychological consequences of treatment for hepatitis C: a community-based evaluation of patient-reported outcomes. Patient 2013, 6:23-34. [PubMed PMID: 23420134; PubMed Central PMCID: PMC3619379]. 10.1007/s40271-013-0005-4.
26. Udina M, Castellvi P, Moreno-Espana J, Navines R, Valdes M, Forns X, et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 2012, 73:1128-1138. [PubMed PMID: 22967776]. 10.4088/JCP.12r07694.
27. Galvao-de Almeida A, Quarantini LC, Batista-Neves S, Lyra AC, Parana R, de Oliveira IR, et al. Is the interferon-alpha-triggered depressive episode a self-limited kind of depression? Four cases of persistent affective symptoms after antiviral treatment in HCV-infected individuals. World J Biol Psychiatry 2010, 11:914-918. [PubMed PMID: 20642400]. 10.3109/15622975.2010.504282.
28. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994, 21:241-243. [PubMed PMID: 7989716].
29. Kajitani K, Kanba S Escitalopram ameliorates prolonged depression with psychotic features induced by interferon therapy for hepatitis C infection: report of 2 cases. Psychosomatics 2013, 54:506-507. [PubMed PMID: 23845321]. 10.1016/j.psym.2013.05.001.
30. Rifflet H, Vuillemin E, Oberti F, Duverger P, Laine P, Garre JB, et al. Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha. Gastroenterol Clin Biol 1998, 22:353-357. [PubMed PMID: 9762223].
31. Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 2012, 57:1379-1390. [PubMed PMID: 22878466]. 10.1016/j.jhep.2012.07.037.
32. American Psychiatric Association Diagnostic and statistical manual for mental disorders 2000, American Psychiatric Association, Washington, DC, [Text Revision ed.]. 4th ed.
33. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59:22-33. [quiz 4-57. PubMed PMID: 9881538].
34. Psychological Corporation Wechsler test of adult reading 2001, Psychological Corporation, San Antonio, TX.
35. Stern R, White T Neuropsychological assessment battery 2003, Psychological Assessment Resources, Lutz, FL.
36. Beck AT Beck Depression Inventory 1996, The Psychological Corporation, San Antonio. 2nd ed.
37. Patterson AL, Morasco BJ, Fuller BE, Indest DW, Loftis JM, Hauser P Screening for depression in patients with hepatitis C using the Beck Depression Inventory-II: do somatic symptoms compromise validity?. Gen Hosp Psychiatry 2011, 33:354-362. [PubMed PMID: 21762832].
38. Argyropoulos SV, Ploubidis GB, Wright TS, Palm ME, Hood SD, Nash JR, et al. Development and validation of the Generalized Anxiety Disorder Inventory (GADI). J Psychopharmacol 2007, 21:145-152. [PubMed PMID: 17329293].
39. Ferentinos P, Kontaxakis V, Havaki-Kontaxaki B, Dikeos D, Lykouras L Psychometric evaluation of the Fatigue Severity Scale in patients with major depression. Qual Life Res 2011, 20:457-465. [PubMed PMID: 20953713].
40. Kleinman L, Zodet MW, Hakim Z, Aledort J, Barker C, Chan K, et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 2000, 9:499-508. [PubMed PMID: 11190005].
41. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46:1121-1123. [PubMed PMID: 2803071].
42. Cleeland CS, Ryan KM Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 1994, 23:129-138. [PubMed PMID: 8080219].
43. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004, 20:309-318. [PubMed PMID: 15322437].
44. Tan G, Jensen MP, Thornby JI, Shanti BF Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain 2004, 5:133-137. [PubMed PMID: 15042521].
45. Loftis JM, Patterson AL, Wilhelm CJ, McNett H, Morasco BJ, Huckans M, et al. Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study. J Psychosom Res 2013, 74:57-63. [PubMed PMID: 23272989]. 10.1016/j.jpsychores.2012.10.012.
46. Huckans M, Fuller BE, Olavarria H, Sasaki AW, Chang M, Flora KD, et al. Multi-analyte profile (MAP) analysis of plasma immune proteins: Altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis C virus infection. Brain Behav 2014, 4:123-142. [PubMed PMID: 24683507].
47. Leonard B, Maes M Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012, 36:764-785. [PubMed PMID: 22197082].
48. Loftis JM, Huckans M, Ruimy S, Hinrichs DJ, Hauser P Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci Lett 2008, 430:264-268. [PubMed PMID: 18063307].
49. Hoge EA, Brandstetter K, Moshier S, Pollack MH, Wong KK, Simon NM Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. Depress Anxiety 2009, 26:447-455. [PubMed PMID: 19319993].
50. Hou R, Baldwin DS A neuroimmunological perspective on anxiety disorders. Hum Physiol 2012, 27:6-14. [PubMed PMID: 22213434].
51. Arnett SV, Clark IA Inflammatory fatigue and sickness behaviour - lessons for the diagnosis and management of chronic fatigue syndrome. J Affect Disord 2012, 141:130-142. [PubMed PMID: 22578888].
52. Alexander GM, Peterlin BL, Perreault MJ, Grothusen JR, Schwartzman RJ Changes in plasma cytokines and their soluble receptors in complex regional pain syndrome. J Pain 2012, 13:10-20. [PubMed PMID: 22172450].
53. de Oliveira CM, Sakata RK, Issy AM, Gerola LR, Salomao R Cytokines and pain. Rev Bras Anestesiol 2011, 61:255-259. [60-5, 137-42. PubMed PMID: 21474032].
54. Slade GD, Conrad MS, Diatchenko L, Rashid NU, Zhong S, Smith S, et al. Cytokine biomarkers and chronic pain: association of genes, transcription, and circulating proteins with temporomandibular disorders and widespread palpation tenderness. Pain 2011, 152:2802-2812. [PubMed PMID: 22000099].
55. Starkweather AR, Lyon DE, Schubert CM Pain and inflammation in women with early-stage breast cancer prior to induction of chemotherapy. Biol Res Nurs 2013, 15:234-241. [PubMed PMID: 22084403].
56. Stedman CA Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol 2013, 28:38-45. [PubMed PMID: 23137126]. 10.1111/jgh.12028.
57. Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Mullhaupt B, et al. Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther 2013, 18:1015-1019. [PubMed PMID: 23558093]. 10.3851/IMP2567.
58. Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Mullhaupt B, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013, 369:630-639. [PubMed PMID: 23944300]. 10.1056/NEJMoa1213557.
59. Bacon BR Managing hepatitis C. Am J Manage Care 2004, 10:S30-S40. [PubMed PMID: 15084065].
60. Loftis JM, Hauser P Risk and protective factors in interferon-induced depression: treatment strategies and clinical outcomes. Dir Psychiatry 2008, 28:227-242.
61. Rifai MA, Loftis JM, Hauser P Interferon-alpha treatment of patients with Hepatitis C: the role of a comprehensive risk-benefit assessment. CNS Drugs 2005, 19:719-721. [author reply 21-2. PubMed PMID: 16097855].
62. Schaefer M, Sarkar R, Diez-Quevedo C Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction. Clin Infect Dis 2013, 57:S111-S117. [PubMed PMID: 23884058]. 10.1093/cid/cit266.
63. Jiang HY, Deng M, Zhang YH, Chen HZ, Chen Q, Ruan B Specific serotonin reuptake inhibitors prevent interferon-alpha-induced depression in patients with hepatitis C: a meta-analysis. Clin Gastroenterol Hepatol 2013, [PubMed PMID: 23648373]. 10.1016/j.cgh.2013.04.035.
64. Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, et al. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics 2010, 51:401-408. [PubMed PMID: 20833939; PubMed Central PMCID: PMC2994596]. 10.1176/appi.psy.51.5.401.
65. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007, 103:83-90. [PubMed PMID: 17292481]. 10.1016/j.jad.2007.01.007.
66. Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, et al. Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med 2012, 157:94-103. [PubMed PMID: 22801672]. 10.7326/0003-4819-157-2-201207170-00006.